Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 7/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | UBE2M | P61081 | 1/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13862600 | 0.92 | MGLL (0.44) | MGLLKDRUBE2MDCUN1D1CSF1R | |
| SCHEMBL2888423 | 0.85 | GAA (0.47) | MGLLKDRTRPV1UBE2MDCUN1D1 | |
| SCHEMBL2894417 | 0.84 | HSD17B1 (0.41) | KDRUBE2MDCUN1D1LMNA | |
| SCHEMBL2888454 | 0.83 | PNLIP (0.46) | MAPTLMNA | |
| SCHEMBL643168 | 0.83 | GAA (0.60) | MGLLKDRSMN1; SMN2UBE2MDCUN1D1 | |
| SCHEMBL13028224 | 0.82 | KDR (0.52) | MGLLKDRSMN1; SMN2ACKR3 | |
| SCHEMBL2884715 | 0.82 | CCR5 (0.44) | UBE2MDCUN1D1 | |
| SCHEMBL27851365 | 0.77 | MTNR1B (0.49) | SMN1; SMN2LMNA | |
| SCHEMBL13862599 | 0.77 | GAA (0.47) | MGLLTRPV1GAAPKMLMNA | |
| SCHEMBL642196 | 0.76 | GAA (0.56) | MGLLSMN1; SMN2GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8558028-B2 | Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase | UNIVERSITY OF BATH OF CLAVERTON DOWN (GB) | 2013-10-15 | — | — | US | disclosed |
| US-8558028-B2 | Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase | UNIVERSITY OF BATH OF CLAVERTON DOWN (GB) | 2013-10-15 | — | — | US | disclosed |
| US-8558028-B2 | Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase | UNIVERSITY OF BATH OF CLAVERTON DOWN (GB) | 2013-10-15 | — | — | US | disclosed |
| US-20100286204-A1 | COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286204-A1 | COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286204-A1 | COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2220026-A2 | INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGENASE | Sterix Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009066072-A2 | COMPOUND | STERIX LIMITED (GB) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009066072-A2 | COMPOUND | STERIX LIMITED (GB) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286204-A1 | COMPOUND CAPABLE OF INHIBITING 17-BETA HYDROXYSTERIOD DEHYDROGENASE | HSD17B13, HSD17B3, HSD3B2 | MGLL 1418/4885KDR 2668/4885SMN1; SMN2 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.